Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Statement re. Media Comment

15 Jun 2021 10:49

RNS Number : 9486B
Omega Diagnostics Group PLC
15 June 2021
 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

 

Statement re. Media Comment

 

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes the recent media comment that Mologic Ltd have requested for Porton Down to evaluate their lateral flow antigen test with an independent party observing.

 

This process has no implications on the UK Government manufacturing contract that Omega has in place with the Department of Health and Social Care ("DHSC"). Under that contract Omega will provide manufacturing capacity for COVID-19 lateral flow antigen tests utilising the key pieces of manufacturing equipment loaned by the UK Government for that purpose and Omega will manufacture whichever test is approved for use by the DHSC. As clarified on 7 June 2021 the ability to supply tests that are produced within the UK remains a key priority for the DHSC and to that end the DHSC have facilitated initial commercial discussions between Omega and a number of companies with lateral flow antigen tests to potentially provide UK manufacturing services.

 

As already announced on 8 June 2021 Omega is in the process of seeking CE marking of its VISITECT® COVID-19 Antigen test, as a self-test. Final preparations for a submission to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) for this test is also underway.

 

Recently published study data confirms that Mologic's lateral flow antigen test, being commercialised by Omega as the VISITECT® COVID-19 Antigen test, demonstrates high diagnostic accuracy (specificity and sensitivity) fulfilling WHO target accuracy with a high sensitivity (93.2%-98.4%) detecting individuals with high viral load infections (Ct

 

Further details of the study and the FIND report can be seen using the links below:

https://www.londonstockexchange.com/news-article/ODX/positive-data-for-covid-19-antigen-test/14998113

https://www.londonstockexchange.com/news-article/ODX/positive-data-for-mologic-covid-19-antigen-test/14963499

 

 Contacts: 

 

Omega Diagnostics Group PLC

www.omegadiagnostics.com

Colin King, Chief Executive

via Walbrook PR

Kieron Harbinson, Group Finance Director

 

 

 

finnCap Ltd

Tel: 020 7220 0500

Geoff Nash/Edward Whiley (Corporate Finance)

 

Alice Lane (ECM)

 

 

 

Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
SPCEANKSFLKFEEA
Date   Source Headline
9th Oct 20097:00 amRNSTrading Update
2nd Oct 20093:20 pmRNSHolding(s) in Company
2nd Oct 20093:04 pmRNSHolding(s) in Company
2nd Oct 200912:16 pmRNSHolding(s) in Company
2nd Oct 20098:53 amRNSHolding(s) in Company
30th Sep 20097:00 amRNSHolding(s) in Company
30th Sep 20097:00 amRNSHolding(s) in Company
25th Sep 20097:00 amRNSIssue of equity and acquisition
27th Aug 200911:56 amRNSAGM Statement
17th Jul 20099:00 amRNSAnnual Financial Report
16th Jul 20097:00 amRNSUK Distribution agreement for Genesis products
7th Jul 20097:00 amRNSFinal Results
4th Jun 20097:00 amRNSHolding(s) in Company
26th May 20097:00 amRNSLaunch of quality performance product
6th Apr 20093:03 pmRNSDirector/PDMR Shareholding
2nd Apr 200911:41 amRNSTrading Statement
20th Mar 20092:00 pmRNSChange of Adviser
12th Dec 20083:48 pmRNSDirector/PDMR Shareholding
27th Nov 20087:00 amRNSInterim Results
11th Nov 20087:00 amRNSTrading Statement
8th Oct 20083:57 pmRNSChange of Adviser Name
28th Aug 20081:24 pmRNSAGM Statement
12th Aug 200810:51 amRNSIssue of Equity / Directors'
18th Jul 200811:30 amRNSAnnual Report and Accounts
7th Jul 20087:00 amRNSFinal Results
12th Jun 20087:00 amRNSNotice of Results
10th Apr 20087:18 amRNSTrading Statement
12th Mar 200811:59 amRNSDirector/PDMR Shareholding
11th Mar 20082:19 pmRNSDirector/PDMR Shareholding
4th Mar 20087:01 amRNSDirector/PDMR Shareholding
10th Jan 20082:28 pmRNSHolding(s) in Company
7th Dec 20077:01 amRNSInterim Results
28th Sep 20077:01 amRNSTotal Voting Rights
26th Sep 20077:01 amRNSNotifiable Interest
3rd Sep 20078:00 amRNSCompletion of Acquisition
3rd Sep 20078:00 amRNSTotal Voting Rights
31st Aug 20071:27 pmRNSDirectors' Dealings
31st Aug 20078:21 amRNSGenesis-CNS Interim Results
31st Aug 20078:00 amRNSCancellation - 31/08/07
30th Aug 200712:56 pmRNSResult of EGM
15th Aug 20078:23 amRNSCompliance with AIM Rule 26
13th Aug 200710:22 amRNSSchedule 1 -Omega Diagnostics
8th Aug 200712:26 pmRNSAGM Statement
6th Aug 20077:01 amRNSAcquisition and placing
6th Aug 20077:00 amRNSRestoration-Omega Diagnostics
6th Aug 20077:00 amRNSChange of Adviser
12th Jul 20071:30 pmRNSStatement re. Suspension
12th Jul 20071:30 pmRNSSuspension-Omega Diagnostics
26th Jun 20077:01 amRNSFinal Results
18th Apr 20074:50 pmRNSAccounting Reference Date

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.